AU3202797A - Inactivation resistant factor viii - Google Patents

Inactivation resistant factor viii

Info

Publication number
AU3202797A
AU3202797A AU32027/97A AU3202797A AU3202797A AU 3202797 A AU3202797 A AU 3202797A AU 32027/97 A AU32027/97 A AU 32027/97A AU 3202797 A AU3202797 A AU 3202797A AU 3202797 A AU3202797 A AU 3202797A
Authority
AU
Australia
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32027/97A
Other languages
English (en)
Inventor
Kagehiro Amano
Randal J. Kaufman
Steven W. Pipe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU3202797A publication Critical patent/AU3202797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU32027/97A 1996-04-24 1997-04-24 Inactivation resistant factor viii Abandoned AU3202797A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US60016117 1996-04-24
US1778596P 1996-05-15 1996-05-15
US60017785 1996-05-15
PCT/US1997/006563 WO1997040145A1 (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Publications (1)

Publication Number Publication Date
AU3202797A true AU3202797A (en) 1997-11-12

Family

ID=26688196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32027/97A Abandoned AU3202797A (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Country Status (10)

Country Link
US (2) US6838437B2 (2)
EP (3) EP0910628B1 (2)
JP (2) JP3987114B2 (2)
AT (2) ATE502958T1 (2)
AU (1) AU3202797A (2)
CA (1) CA2252896C (2)
DE (2) DE69735421T2 (2)
DK (1) DK1754718T3 (2)
PT (1) PT1754718E (2)
WO (1) WO1997040145A1 (2)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833848T3 (da) * 1995-06-12 2001-11-05 Sanquin Bloedvoorziening Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
WO1999041385A1 (en) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
EP1351986A2 (en) * 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
JP2008525381A (ja) * 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
KR20080007226A (ko) * 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
SG10201509149VA (en) * 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
CN103889445A (zh) 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
WO2014041500A2 (en) * 2012-09-12 2014-03-20 Centre For Bioseparation Technology-Vit Double mutant coagulation factor viii and methods thereof
SG11201503719WA (en) * 2012-11-29 2015-06-29 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)
US9657111B2 (en) 2012-11-29 2017-05-23 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein C and uses thereof
JP6523244B2 (ja) * 2013-03-15 2019-05-29 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 変異体第ｖｉｉｉ因子ポリペプチドならびにそれらの製造方法および使用方法
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
DK3265489T3 (da) * 2015-03-06 2019-07-15 CSL Behring Lengnau AG Forbindelser til forbedring af halveringstiden af von willebrand faktor
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
AU2017205776B2 (en) 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
EP3870206A4 (en) * 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JP2525022B2 (ja) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
NZ236094A (en) 1989-11-17 1993-04-28 Chiron Corp Recombinant protein complex having human factor viii:c activity
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
CA2252896C (en) * 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii

Also Published As

Publication number Publication date
DK1754718T3 (da) 2011-07-18
JP2007228973A (ja) 2007-09-13
US6838437B2 (en) 2005-01-04
EP1754718A3 (en) 2007-05-16
PT1754718E (pt) 2011-07-13
ATE319817T1 (de) 2006-03-15
DE69735421T2 (de) 2006-10-19
EP0910628A1 (en) 1999-04-28
DE69735421D1 (de) 2006-05-04
CA2252896A1 (en) 1997-10-30
JP3987114B2 (ja) 2007-10-03
US20060014683A1 (en) 2006-01-19
EP0910628A4 (en) 2001-05-02
EP2202242A1 (en) 2010-06-30
EP1754718B1 (en) 2011-03-23
JP4250661B2 (ja) 2009-04-08
JP2000511407A (ja) 2000-09-05
WO1997040145A1 (en) 1997-10-30
EP1754718A2 (en) 2007-02-21
US7459534B2 (en) 2008-12-02
CA2252896C (en) 2009-03-10
EP0910628B1 (en) 2006-03-08
DE69740154D1 (de) 2011-05-05
US20020132306A1 (en) 2002-09-19
ATE502958T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
PT1754718E (pt) Factor viii resistente à inactivação
AU5298293A (en) Chimeric factor viii
AU645539B2 (en) A recombinant human factor VIII derivative
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
EP0442961A1 (en) HYBRID PROCOAGULATING PROTEINS.
UA48105C2 (uk) ФРАГМЕНТ ДНК, ЯКИЙ КОДУЄ БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), РЕКОМБІНАНТНА МОЛЕКУЛА ДНК (ВАРІАНТИ), КЛІТИНА-ХАЗЯЇН (ВАРІАНТИ), СПОСІБ ОДЕРЖАННЯ БІЛКУ РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), АНТИТІЛО АБО ФРАГМЕНТ АНТИТІЛА (ВАРІАНТИ), МОЛЕКУЛА КДНК (ВАРІАНТИ)
AU3498189A (en) Fibronectin binding protein
EP0731636A4 (en) APOPTOSIS-MODULATING PROTEINS, DNA-ENCODING, AND METHOD FOR THEIR USE
EP0270618A1 (en) Novel procoagulant proteins
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
AU3793493A (en) Therapeutic domains of von willebrand factor
MX9708426A (es) Polipeptido hk2 de variante estable.
EP0665888A4 (en) ALLERGEN FROM RAYGRASS POLLEN.
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
MX9806041A (es) Proteina purificada sr-p70.
EP0576426A4 (2)
AU3711597A (en) A novel galanin receptor
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure